Stocks-6185.HK-CanSino Biologics Inc

6185.HK CanSino Biologics Inc

41.99 -0.40 (-0.94%)
Prices By Xignite, in HKD Market Closed
Invest
Invest

Performance

-11.84% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
10.36B
Day’s Range
41.69
-
42.69
52W Range
39.99
-
146.78
Volume (3M)
1.57M
Price-Earnings Ratio
-10.21
Revenue
1.21B
Pinned Post
Edited
eToro Team
📢 Please be informed that due to an issue from our liquidity provider that is currently under investigation the HK stocks were not available for the whole daily session. Thank you, - The eToroTeam
Like CommentShare
Show more comments2 of 12
1 reply
1 reply
null
.
Top Discussions
MarketUpdates
$6185.HK (CanSino Biologics Inc) Q1 2023 earnings report is expected to be released
27
APR
REPORTS
CanSino Biologics Inc Q1 2023 earnings report is expected to be released after market open
Notify me
6185.HK
6185.HK
CanSino Biologics Inc
41.99
-0.40
(-0.94%)
Trade
Andrejs Koskevics
My absolutely worst positions are: $888.L (888 Holdings) -64,13% $LUMN (Lumen Technologies Inc) -59,15% $6185.HK (CanSino Biologics Inc) -56,65% $SSSS (SuRo Capital Corp) -53,72% For me is more important to concentrate on making conclusions about what gone wrong and how such investments could be avoided... Show More
Like CommentShare
Show more comments2 of 4
null
.
MarketUpdates
Edited
$6185.HK (CanSino Biologics Inc) Q4 2022 earnings report is expected to be released
27
MAR
REPORTS
CanSino Biologics Inc Q4 2022 earnings report released after market open
6185.HK
6185.HK
CanSino Biologics Inc
41.99
-0.40
(-0.94%)
Trade
Andrejs Koskevics
$6185.HK (CanSino Biologics Inc) Looks like it was mistake to invest in this stock. Will hold it, but no further investment in couple next years.
MarketUpdates
Edited
$6185.HK (CanSino Biologics Inc) Q4 2022 earnings report is expected to be released

About CanSino Biologics Inc

CanSino Biologics Inc. is a biotechnology and biopharmaceuticals company based in the People’s Republic of China. Originally founded in 2009, CanSino Biologics is primarily focused on the clinical stage vaccine market segment. The company has an international focus in terms of distribution and is currently headquartered in Tianjin in the People’s Republic of China. CanSino Biologics Inc. is listed on the Hong Kong Stock Exchange (HKEX) under the 6185.HK ticker. In terms of the performance of the 6185.HK share price, Cansino Biologics Inc. has posted a 52-week high of 285.20 HKD to a 52-week low of 32.90 HKD. It has been traded on the HKEX since it was first listed in July 2018. CanSino Biologics Inc.’s main commercial interests lie in the development and manufacture of vaccines. Some of its most high-profile vaccines include an Ebola virus vaccine, as well as vaccines for the prevention of N. meningitides. In 2020, CanSino Biologics Inc. signed a collaboration agreement with The National Research Council of Canada and Precision NanoSystems Inc. to develop vaccines to combat COVID-19. It was one of the first companies to secure a patent for its COVID-19 vaccine in China. To keep up to date with the latest news, updates, and financial data on the CanSino Biologics Inc. stock, simply add the 6185.HK ticker to your eToro watchlist.
2.2K
Employees
HK
HQ
2009
Founded
Xue Feng Yu, PhD
CEO
Show More

Upcoming Earnings

27
APR
REPORTS
CanSino Biologics Inc Q1 2023 earnings report is expected to be released after market open

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
59
High
Industry 
Avg. 45 
60
Environment
71
Social
46
Governance

People Also Bought